As of June 4, 2025, Noxxon Pharma NV (ALNOX.PA) reports a Forward P/E of N/A.
Forward P/E gauges the price investors pay for each dollar of anticipated earnings, offering insight into a stock's future valuation.
Comparing Noxxon Pharma NV's Forward P/E to Peers
To better understand Noxxon Pharma NV's position, it's useful to compare its Forward P/E against industry peers. Below are selected comparisons:
| Company | Forward P/E |
|---|---|
| Noxxon Pharma NV (ALNOX.PA) | - |
| Biotest AG (BIO.DE) | 28.38 |
| Sprint Bioscience AB (SPRINT.ST) | 0.88 |
Compared to its competitors, Noxxon Pharma NV's Forward P/E is difficult to compare due to insufficient data.